Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
The most effective method to Promoter for Cutthroat Medical attendant Compensations in Your Medical services Office - 2'Dancing With the Stars' Season 34 finale: Who might win the mirror ball trophy? Where do the remaining contestants rank?
- 3Experience Unrivaled Sound: Top Speakers You Really want to Hear
- 4Cheetah, Hammerhead Shark, and 38 Other Animals in Danger of Extinction Receive New International Protections from U.N.
- 5How comfort foods trigger pleasure in our brains
- The 1 question we have to ask ourselves about the Taylor Frankie Paul 'Bachelorette' scandal
- Artemis 2 astronauts arrive at Kennedy Space Center ahead of NASA's historic launch around the moon
- Sophie Kinsella, 'Confessions of a Shopaholic' author, dies at 55 after battle with cancer
- Von der Leyen: Paris meeting sends signal of unity for Ukraine
- New research reveals urban raccoons across the US show early signs of domestication
- Inn The executives: A Remunerating Profession Decision for Energetic People
- Pick Your Favored kind of soup
- What to watch for in weight loss drugs in 2026
- Genome study reveals milestone in history of cat domestication
